Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 50

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 50
---
 | $    |          — |   |
| Deemed dividends on make whole shares and warrants                          |     | $                        |  1,845,839 |   |     | $    |          — |   |
| Issuance of pre-funded preferred shares in private placement offerings, net |     | $                        |     11,799 |   |     | $    |          — |   |
| Conversion of preferred participation certificates into common shares       |     | $                        |      6,966 |   |     | $    |          — |   |
| Accrued dividends on preferred shares                                       |     | $                        |    126,367 |   |     | $    |          — |   |

The accompanying notes are an integral part of these unaudited interim condensed financial statements.

Annex A-5 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Note 1 Background: NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the “Company”) and its wholly -ownedsubsidiaries NLS Pharmaceutics (Israel) Ltd., an Israeli company (the “Merger Sub”) and NLS Pharmaceutics Inc., a Delaware corporation, (“NLS Inc.”), is an emerging biopharmaceutical company engaged in the discovery and development of life -improvingdrug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as attention deficit hyperactivity disorder (“ADHD”). The Company’s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD. The accompanying consolidated financial statements include the results of the Company, NLS Inc. and the Merger Sub. All references hereinafter to the Company mean the Company and its subsidiaries NLS Inc. and the Merger Sub. On January 7, 2025, the Company convened an extraordinary shareholders’ meeting (the “Meeting”), at which the shareholders approved the proposal of the Board of Directors to reduce the nominal value of each registered share (common and preferred shares, if any) and each preferred participation certificate (if any) equally to CHF 0.03($ 0.0369) per share, with the released amounts to be allocated to the Company’s